Combo drugs strong in the COPD treatment market
By Son, Hyung-Min | translator Kim, Jung-Ju
23.10.24 12:10:53
가나다라
0
Sales of LAMA+LABA combo rise 11% YoY… records KRW 10.3 billion in prescriptions
Domestic and international COPD treatment guidelines also recommend the prescription of combination therapy... increases the momentum
The growth of the combination drugs was notable in the chronic obstructive pulmonary disease (COPD) treatment market in Q3 this year. With major COPD treatment guidelines recommending a long-acting muscarinic antagonist (LAMA) and long-acting beta2 agonist (LABA), the prescription trend appears to have shifted toward combination drugs. In particular, the growth of the LAMA+LABA combination drugs owned by GlaxoSmithKline (GSK) and Boehringer Ingelheim (BI) had stood out.
▲Presciptions of LAMA+LABA combos (Source: UBIST).
According to the market research institution UBIST on the 23rd, the amount of outpatient prescriptions for LAMA+LABA combination drugs in Q3 amounted to KRW 10.3 billion. This is a 10.8% YoY increase from last year. The bronchodi
Son, Hyung-Min(shm@dailypharm.com)
If you want to see the full article, please JOIN US (click)